한빛사논문
Min Hak Lee 1,2,3,5, Bada Lee 1,2,5, Se Eun Park 1, Ga Eul Yang 4, Seungwoo Cheon 4, Dae Hoon Lee 1,2, Sukyeong Kang 2, Ye Ji Sun 1,2,3, Yongjin Kim 4, Dong-sub Jung 4, Wonwoo Kim 4, Jihoon Kang 4, Yi Rang Kim 3,4,* and Jin Woo Choi 1,2,3,*
1College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
2Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
3Department of Pharmacology, Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul 02447, Republic of Korea.
4Center for Research and Development, Oncocross Ltd, Seoul 04168, Republic of Korea.
5These authors contributed equally: Min Hak Lee, Bada Lee.
*Corresponding authors: correspondence to Yi Rang Kim or Jin Woo Choi
Abstract
Sarcopenia, the progressive decline in skeletal muscle mass and function, is observed in various conditions, including cancer and aging. The complex molecular biology of sarcopenia has posed challenges for the development of FDA-approved medications, which have mainly focused on dietary supplementation. Targeting a single gene may not be sufficient to address the broad range of processes involved in muscle loss. This study analyzed the gene expression signatures associated with cancer formation and 5-FU chemotherapy-induced muscle wasting. Our findings suggest that dimenhydrinate, a combination of 8-chlorotheophylline and diphenhydramine, is a potential therapeutic for sarcopenia. In vitro experiments demonstrated that dimenhydrinate promotes muscle progenitor cell proliferation through the phosphorylation of Nrf2 by 8-chlorotheophylline and promotes myotube formation through diphenhydramine-induced autophagy. Furthermore, in various in vivo sarcopenia models, dimenhydrinate induced rapid muscle tissue regeneration. It improved muscle regeneration in animals with Duchenne muscular dystrophy (DMD) and facilitated muscle and fat recovery in animals with chemotherapy-induced sarcopenia. As an FDA-approved drug, dimenhydrinate could be applied for sarcopenia treatment after a relatively short development period, providing hope for individuals suffering from this debilitating condition.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기